T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma.
For nearly 20 yrs, we used T/Tn antigen vaccine in safe, specific, effective, long-term intradermal vaccination against recurrence of advanced breast carcinoma. Treatment is ad infinitum. All 18 breast carcinoma patients treated, pTNM Stages IV (6), III (6), and II (6), survived > 5 yrs postoperatively; 10 survived > 10 to > 18 yrs; of the latter, three patients each are Stages III and IV. Five additional 5 yr survivors have not yet reached 10 yrs. The probability that our survival results are due to chance, with NCI "1991 Standard PDQ Data" as control, for all three stages taken together is: 5-yr survival: p < 1 x 10(-8); 10-yr survival: p < 1 x 10(-5). There were no untoward side effects. The vaccination area presented as a delayed-type hypersensitivity reaction, but at variance with the PPD reaction, with significant inflammation, increase of helper T lymphocytes and decrease of the T suppressor/cytotoxic cell ratio.
Springer
G F
GF
H.M. Bligh Cancer Research Laboratories, Chicago Medical School, Illinois 60064.
Desai
P R
PR
Tegtmeyer
H
H
Carlstedt
S C
SC
Scanlon
E F
EF
D000328:Adult; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009367:Neoplasm Staging; D010865:Pilot Projects; D015996:Survival Rate; D016896:Treatment Outcome; D014611:Vaccination; D014612:Vaccines
D015295:Antigens, Tumor-Associated, Carbohydrate; C040286:Tn antigen; D014612:Vaccines; C016467:Thomsen-Friedenreich antigen